Investing News Network

Markets
TSX19258.32+195.41
TSXV652.36+5.03
DOW31438.26-62.42
S&P 5003900.11-11.63
NASD11524.55-83.07
ASX6706.00+177.60
Commodities
Gold1824.28+0.85
Silver21.04-0.11
Copper3.76-0.01
Palladium1880.50+12.50
Platinum909.00+2.00
Oil110.68+1.11
Heating Oil4.17+0.05
Natural Gas6.44-0.06
Currencies
BTCUSD20635.07-217.68
USDCAD1.2871-0.0001
USDEUR0.9455+0.0003
USDGBP0.8152-0.0001
USDAUD1.4445-0.0002
USDJPY135.30-0.15

Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing

Financing from new and existing investors will support continued development of a novel treatment for food allergy

Jim Momtazee and George Montgomery to join Alladapt's Board of Directors

Keep reading... Show less

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets

Novartis agreement marks second recent major transaction to leverage Voyager's TRACER technology following October 2021 Pfizer agreement

Keep reading... Show less

Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022.

"I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and build our commercial capabilities to support the launch of this initial product and future next-gen cell therapies within our MAGE-A4 franchise. Her fresh perspective and leadership abilities will support our continued growth in our mission to design and develop cell therapies for people with cancer," said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer.

Keep reading... Show less
×